Our leadership team

Chief Communications & Corporate Marketing Officer

Kate Dobbs is a collaborative, results-oriented and strategic leader who excels at leading through change and thrives in environments that offer opportunities to build and transform. As Chief Communications & Corporate Marketing Officer at Solventum, Kate leads the team responsible for communications and reputation management, brand and creative strategy, and marketing enablement and operations. With more than 25 years of experience across healthcare, pharmaceutical, business-to-business and retail, Kate brings a deep understanding of how to connect with and engage diverse audiences and is known for fostering innovation and developing high-performing teams.  

Prior to Solventum, Kate was Chief Marketing Officer at Interwell Health and Senior Vice President of Marketing & Communications at Fresenius Medical Care, both leaders in the kidney care space. Earlier in her career, Kate was Senior Director of Corporate Communications at Vertex Pharmaceuticals and spent over a decade at Staples in various roles in the U.S. and Europe. 

Chief Strategy & Corporate Development Officer

Rachel Ellingson is a seasoned healthcare executive and former investment banker with more than 30 years of experience, known for her strategy and active portfolio management expertise and ability to build strong, high-impact teams. She brings significant leadership experience having led strategy, M&A and divestiture execution, as well as investor relations and communications in the medtech industry. As Chief Strategy & Corporate Development Officer, she is focused on setting the company’s strategic direction and portfolio transformation roadmap, and executing inorganic actions to drive our long-term growth strategy.

Prior to joining Solventum, Rachel served as Chief Administrative Officer and Chief Strategy Officer at Zimmer Biomet, where she had global oversight of strategy, business development, integration and separation management, as well as marketing and communications. Prior to that, Rachel held similar roles with St. Jude Medical from 2011 through its acquisition by Abbott in 2017. Rachel started her career in investment banking and ultimately rose to Managing Director with Bank of America's Healthcare Investment Banking Group. 

Chief Human Resources Officer

Tammy Gomez is passionate about fostering positive work environments and corporate cultures that put people first and are the most preferred places to work. With more than two decades of human resources experience in the healthcare and health services industry, she leads Solventum’s organization-wide policies and programs that attract, support, motivate and develop our team of solvers. 

Before joining Solventum, Tammy was Executive Vice President and Chief Human Resource Officer at Owens & Minor. She also spent more than 20 years at Cardinal Health in various roles of increasing responsibility, including most recently leading its Global HR Center of Excellence & HR Services team. She began her career in finance and worked with Prudential and General Motors.

Chief Supply Chain Officer

Paul Harrington is a strategic leader and decisive thinker known for his strong work ethic, global mindset and drive to win. As Chief Supply Chain Officer, Paul oversees Solventum’s plants and distribution centers, while also leading logistics, sourcing, engineering, facilities, real estate and environment, health and safety functions under supply chain. 

Paul has extensive global manufacturing, operations and medtech experience. He spent 10 years at Medtronic where he was most recently Senior Vice President, Global Operations Innovation responsible for shaping, transforming and innovating across the global operations and supply chain function. He also previously served as Vice President Global Operations for the Restorative Therapies Group and Neuromodulation business unit. Prior to joining Medtronic, he was Vice President of Global Manufacturing at Covidien. 

Chief Legal Affairs Officer

Marcela Kirberger is an impactful and highly effective global leader known for guiding medtech and life sciences companies through complex business expansion strategies and organizational transformations. As Chief Legal Affairs Officer, she leads the legal, government affairs, global security and ESG teams and is responsible for establishing the strategy for these functions as well as managing the company’s global regulatory compliance and commercial legal and intellectual property matters.

Prior to joining Solventum, Marcela was General Counsel and Corporate Secretary at Elanco, responsible for the global strategy and operations of the legal, government affairs, ESG and ERM areas. Her deep healthcare legal experience also includes U.S., regional and global leadership roles with companies such as Novartis, Roche and Danaher. Prior to joining the Novartis companies in 2006, Marcela was a securities litigator at Lowenstein Sandler in New Jersey. 

Chief Commercial Officer

Heather Knight is a strategic and people-first medtech leader who thrives on building high-performing teams that deliver results. As Chief Commercial Officer at Solventum, Heather oversees global commercial and R&D operations across the company’s MedSurg, Dental Solutions and Health Information Systems segments. She is focused on accelerating growth through coordinated execution, market development and innovation that empowers healthcare professionals and improves patient outcomes.

Heather brings more than 30 years of experience in the healthcare industry, including leadership roles in general management, upstream innovation and commercial strategy at Baxter, Medtronic, Covidien, Tyco Healthcare and Kendall. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sales across three business segments, as well as R&D, supply chain and medical and regulatory affairs. She also served as interim Group President of Baxter’s Medical Products and Therapies segment, its largest business unit. She currently serves on the Board of Directors of Waters Corporation and is deeply committed to mentorship, volunteerism and advancing inclusion and diversity across the industry.

Chief Information & Digital Officer

Amy Landucci is known for building high-performing teams and has a proven track record of delivering digital and technology transformations within healthcare. As Solventum’s Chief Information & Digital Officer, she works closely with the business and technology leaders to create a world-class digital technology platform that carefully aligns to the company’s overall business strategy enabling global operations to accelerate innovation and growth. 

Prior to joining Solventum, Amy was Chief Digital and Technology Officer at Haleon, where she led the technical carveout from GSK to form the world’s largest standalone consumer healthcare company. Prior to GSK, she spent a decade at Novartis in a variety of roles. The first eight years of her career was in consulting with Accenture. Amy has served on the Board of Directors for Healthy Women, the leading independent, non-profit health information source for women in the United States.

Chief Financial Officer

Wayde McMillan is known for his finance expertise, deep understanding of the medtech industry and ability to build strong teams. He brings more than 25 years in finance, driving profitable growth in ever-changing environments for leading global and innovative companies. As CFO of Solventum, he is focused on the company’s mission, positioning Solventum for long-term success and creating long-term value for shareholders.

Prior to joining Solventum, Wayde served as Executive Vice President, CFO of innovative medical device company Insulet. He also previously served as CFO and Vice President of Finance of the $8 billion Minimally Invasive Therapies Group at Medtronic and held numerous leadership positions at Covidien from November 2006 until Medtronic’s acquisition of the company in January 2015. Wayde started his career in accounting, audit, financial analysis, and investor relations.

Senior Vice President, Regulatory Affairs & Quality Assurance

Mike Spears is known for leading organizations that bring innovative products to market, increase customer satisfaction, regulatory compliance, on-time delivery of quality products, and continuous improvements to enhance shareholder value. As Senior Vice President, Regulatory Affairs and Quality Assurance for Solventum, he establishes and delivers quality assurance, regulatory affairs, and compliance strategies, as well as defines and oversees the global quality management system for its worldwide facilities and healthcare-related operations.

Mike has more than 30 years of extensive quality assurance, regulatory and compliance experience with major global medical device companies. Prior to joining Solventum, Mike was Senior Vice President, Regulatory Affairs and Compliance, Insulet Corporation where he provided overall leadership, strategy and management for the development and execution of all worldwide regulatory and compliance issues for its product portfolio. He also held Quality Assurance and Regulatory leadership positions and made an impact at Medtronic, Covidien and Tyco Healthcare.

Former Vice Chairman and Chief Commercial Officer, AbbVie, Inc.

Carlos Albán is a seasoned pharmaceutical executive with more than 30 years of experience in global commercial strategy and operations. From December 2018 until March 2021, Mr. Albán served as Vice Chairman, Chief Commercial Officer of AbbVie, Inc., responsible for global commercial operations, including the Pharmacyclics commercial functions. From January 2013 until December 2018, he served as AbbVie’s Executive Vice President, Commercial Operations. From February 2011 until December 2012, Mr. Albán served as Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial Operations for Abbott Laboratories, Inc., and previously served at Abbott as Senior Vice President, International Pharmaceuticals from 2009 to 2011, as Vice President, Pharmaceuticals, Western Europe and Canada Operations from 2007 to 2009, as Vice President, Pharmaceuticals, European Operations from 2006 to 2007, as Regional Director for the Northern Europe area of the international pharmaceutical business from 2004 to 2006, and General Manager, Portugal from 2002 to 2004. Mr. Albán currently serves on the board of SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Mr. Albán received a degree in economics from Pontificia Universidad Javeriana in Bogotá, Colombia.

Former CEO, Premier Inc.

Susan D. DeVore served as Chief Executive Officer and a member of the Board of Directors of Premier Inc., a leading health care improvement company, from 2013 to May 2021, and also served as President of Premier from 2013 to April 2019. She has served in a consulting capacity for Premier since her retirement in June 2021. Ms. DeVore was President and CEO of a predecessor company, Premier Healthcare Solutions, Inc. from 2009 to 2013 prior to its reorganization, and before that was the Chief Operating Officer for a number of affiliated Premier entities from 2006 to 2009. Prior to joining Premier, Ms. DeVore had two decades of finance, strategy and healthcare consulting experience. Ms. DeVore is also a director of Elevance Health, Inc., serving since August 2021.

Former Partner, EY

From 2002 to 2022, Ms. Edwards distinguished herself as a partner at EY, culminating in her role as Global Client Service Partner from 2017 to 2022. Her career at EY was marked by significant leadership and client service roles, including the stewardship of EY's nearly $4B Assurance practice across 20 countries in the Americas, encompassing 10 regions and a team of over 20,000 professionals. She was instrumental in driving the strategy for audit, forensics, and financial accounting and advisory services throughout the Americas. Beyond her professional achievements, Ms. Edwards has contributed her expertise as a board member and advisor to several esteemed organizations, including the Girl Scouts of the Nation's Capital, Leadership Greater Washington, the Pamplin College of Business Advisory Council at Virginia Tech, and the National Capital Region Advisory Board for the American Red Cross. She holds a Bachelor of Science in Accounting from Virginia Tech.

EVP and CFO, Laboratory Corporation of America Holdings

Glenn A. Eisenberg has served as Executive Vice President and Chief Financial Officer of Laboratory Corporation of America Holdings, since June 2014. From 2002 until joining the Company, he served as the Executive Vice President of Finance and Administration and Chief Financial Officer at The Timken Company, a leading global manufacturer of highly engineered bearings and alloy steels and related products and services. Previously, he served as President and Chief Operating Officer of United Dominion Industries, a diversified industrial manufacturer, now a subsidiary of SPX Corporation, after working in several roles in finance, including Executive Vice President and Chief Financial Officer. Mr. Eisenberg served on the Board of Directors of US Ecology, Inc. until May 2022, where he chaired the Audit Committee; Family Dollar Stores Inc. until July 2015, where he chaired the Audit Committee; Alpha Natural Resources Inc. until May 2015, where he was the lead independent director and chaired the Nominating and Corporate Governance Committee, and Perspecta Inc. until May 2021, where he served on the Audit Committee. Mr. Eisenberg holds a Bachelor of Arts degree from Tulane University and a Master of Business Administration from Georgia State University.

Chief Executive Officer and Managing Partner, Versalius Ventures, Inc.

Dr. Bernard A. Harris Jr., is chief executive officer and managing partner of Vesalius Ventures, Inc. He served as a trustee/director for Salient and Barings investment funds. He currently serves on the boards of Raytheon Technologies (NYSE: RTX), U.S. Physical Therapy (NYSE: USPH) and MassMutual. He also served as a board member for the National Academies of Science, Engineering and Medicine - Board on Health Sciences Policy, and is currently on the boards of the Texas Medical Center and the Harris Foundation, which he founded.  Dr. Harris is a former NASA astronaut, has logged more than 438 hours and traveled over 7.2 million miles in space. He was a mission specialist on the space shuttle Columbia in 1993 and a payload commander on space shuttle Discovery in 1995, where he became the first African American to walk in space.  He earned a Bachelor of Science in Biology from the University of Houston, a Master of Medical Science from the University of Texas Medical Branch at Galveston, a Master of Business Administration from the University of Houston – Clear Lake, and a Doctor of Medicine from Texas Tech University Health Sciences Center School of Medicine. He completed a residency in internal medicine at the Mayo Clinic, a National Research Council Fellowship in endocrinology at the NASA Ames Research Center and trained as a flight surgeon at the United States Air Force School of Aerospace Medicine. He is a fellow of the American College of Physicians, and a member of the American Academy of Arts and Sciences.

Former EVP and CHRO, Mondelez International, Inc.

Karen J. May, who possesses a unique combination of having been both a financial executive and a human resource executive of global companies, brings to the Board extensive operational, financial and human capital strategy experience. Ms. May has been a member of the board of directors of Ace Hardware Corporation, where she is Chair of the Audit and Finance Committee, since 2017. Since 2019, Ms. May is also a member of the board of directors of Alcon, Inc., where she is chair of the Compensation Committee.  Previously, Ms. May was on the board of directors of MB Financial, Inc., where she served as Chair of the Compensation Committee until 2019. From 2012 to 2018, she was the Executive Vice President and Chief Human Resources Officer at Mondelez International, Inc. From 2005 to 2012, Ms. May was the Executive Vice President and Chief Human Resources Officer of Kraft Foods, Inc. Between 1990 and 2005, she held various positions in Human Resources and Finance at Baxter International Inc., including Corporate Vice President and Chief Human Resources Officer, Vice President, International Finance, and Vice President, Division Controller. Prior to Baxter International Inc., Ms. May was a Certified Public Accountant in the audit practice of Price Waterhouse.

Former EVP, Strategy & Business Development, Bristol-Myers Squibb

Elizabeth A. Mily is a 30+ year healthcare and financial industry veteran, serving most recently as the Executive Vice President, Strategy & Business Development, at Bristol-Myers Squibb.  In this role, she oversaw the company strategy and approach to sourcing external innovation, including all business development activities, strategic partnerships, alliance management, mergers and acquisitions, and the company’s broad equity investing portfolio. Elizabeth was appointed to the position in March 2020. Prior to joining Bristol-Myers Squibb, Elizabeth was a senior member of the Global Healthcare Group at Barclays where she led its Lifesciences business, including the BioPharma, Life Science Tools and Diagnostics sectors.  Prior to joining Barclays, Elizabeth served as Senior Vice President, Corporate Strategy and Development at Thermo Fisher Scientific. Before Thermo Fisher, Elizabeth spent 16 years at Goldman, Sachs & Co., where she was a Managing Director and senior coverage officer within the Healthcare Department of the Investment Banking Division.  Elizabeth holds a Master of Science in Foreign Service from Georgetown University and a Bachelor of Arts in German Literature and European History from the Ohio State University.  She was also a Fulbright Scholar to the Universities of Cologne and Hamburg, Germany.  Prior to attending University, Elizabeth completed a Congress-Bundestag scholarship to Germany.  Elizabeth previously served on the Dean’s Advisory Council of the Ohio State University Fisher College of Business and previously served as a Trustee of the Stephen Gaynor School.

Former President and COO, C.R. Bard, Inc.

John H. Weiland served as President and Chief Operating Officer of medical device company C. R. Bard, Inc. from 2003 until 2017, when Bard was acquired by Becton, Dickinson and Company. He also served on Bard’s board of directors from 2005 to 2017, becoming Vice Chairman of the Board in 2016. Mr. Weiland joined Bard in 1996 and held the position of Group President, with global responsibility for several Bard divisions and its worldwide manufacturing operations prior to becoming President and Chief Operating Officer. Prior to Bard, he held senior management positions at Dentsply International, American Hospital Supply, Baxter Healthcare, and Pharmacia AB. Mr. Weiland served on the board of Cardinal Health, Inc. from 2019 to 2022, where he chaired the Risk Oversight Committee. He also brings valuable perspectives and insights from his prior service on the boards of directors of Celgene Corporation, including service on its Audit Committee, and West Pharmaceutical Services’ board of directors, including chairing its Compensation and Finance Committees.

Former SVP, Strategy and Business Development and Licensing, Covidien

Amy A. Wendell was a Senior Advisor for Perella Weinberg Partner’s Healthcare Investment Banking Practice from 2016 to 2019, providing guidance and advice with respect to mergers and acquisitions and divestures for clients and assisting the firm in connection with firm-level transactions. From 2015 to September 2018, Ms. Wendell served as a Senior Advisor for McKinsey’s Strategy and Corporate Finance Practice and also served as a member of McKinsey’s Transactions Advisory Board to help define trends in mergers and acquisitions, as well as help shape McKinsey’s knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including engineering, product management and business development. Most recently, from December 2006 until Covidien’s acquisition by Medtronic plc in January 2015, she served as Senior Vice President of Strategy and Business Development, where she led the company’s strategy and portfolio management initiatives and managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution. Ms. Wendell serves as Lead Director of AxoGen, Inc., where she is a member of the Nominating and Governance Committee and the Audit Committee; at Baxter International, Inc., where she is a member of the Quality, Compliance and Technology Committee and Compensation and Human Capital Committee; and at Hologic, Inc., where she is a member of the Audit and Finance Committee. She also serves on the board of Por Cristo, a non-profit charitable medical service organization involved in health care work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science in mechanical engineering from Lawrence Technological University and a Master of Science degree in biomedical engineering from the University of Illinois.

Former Vice President, Commercial, GE Power, General Electric Company

Darryl Wilson is a strategic business executive who has built highly successful organizations and led complex business transformations at General Electric and British Petroleum businesses around the world for more than 35 years. Darryl was a Vice President and Corporate Officer of the General Electric Company. After leaving GE in 2017, Darryl founded The Wilson Collective, an investment and business advisory firm that advises, consults and invests in a portfolio of businesses. He serves on the NextEra Energy Board of Directors, Audit and Compensation Committees and also serves on the Eaton Corporation Board of Directors, Audit and Governance Committees. He was recently appointed to the Primerica Board of Directors. He served as Chairman of the Board of the Dallas Federal Reserve - Houston Branch; Houston Endowment - Finance and Investment Committees; Texas Children's Hospital - Finance and Public Policy Committees; The Kinkaid School Board of Trustees - Finance and Endowment Committees. Darryl also served on the Dallas Federal Reserve Board, Energy Advisory Committee. Darryl held P&L leader roles based internationally in Canada; Budapest, Hungary; London, England and Shanghai, China. He held CEO roles in Asia Pacific, Europe, Middle East and Africa for GE Consumer and Industrial. He served as President & CEO of GE Aero Derivatives Energy, a global aircraft engine technology business and also served as President & CEO GE Consumer Products EMEA. In his final GE position, Darryl was Vice President, Commercial in the GE Power division, leading global sales and marketing for a $38B provider of power generation, transmission, distribution and services. Darryl joined GE in 1992, after earning an MBA in Marketing from Indiana University. He has a BA in Business Administration from Baldwin Wallace College in Ohio and spent the first six years of his career in the Executive Development Program at British Petroleum North America in Cleveland, Ohio. He has been active in many other community organizations; Darryl is a former Board Member and Executive Committee Member of the Greater Houston Partnership, The Houston Food Bank, The American Heart Association, The Dream Foundation, The East End Neighborhood Center and The Greater Cleveland Urban League. Darryl also served on several corporate boards representing General Electric affiliates, and joint ventures internationally. He was appointed by GE and the US Government to the US and Mexico Energy council.